Anal Fistula

2
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
1
ASCsPhase 31 trial
Active Trials
NCT00475410Completed214Est. Aug 2009
AB
Angiocrine BioscienceCA - San Diego
1 program
1
E-CEL UVECPhase 11 trial
Active Trials
NCT04190862RecruitingEst. Jun 2032

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
TakedaASCs
Angiocrine BioscienceE-CEL UVEC

Clinical Trials (2)

Total enrollment: 214 patients across 2 trials

Efficacy and Safety of Adipose Stem Cells to Treat Complex Perianal Fistulas Not Associated to Crohn´s Disease

Start: Feb 2007Est. completion: Aug 2009214 patients
Phase 3Completed

E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Start: Jan 2020Est. completion: Jun 2032
Phase 1Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 214 patients
2 companies competing in this space